Haleon (HLN) Stock Forecast & Price Target

$10.36 -0.02 (-0.19%)

As of 06/30/2025 03:58 PM Eastern

Haleon - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 11 Analyst Ratings

Sell
0

Hold
5

Buy
6

Based on 11 Wall Street analysts who have issued ratings for Haleon in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 11 analysts, 5 have given a hold rating, 4 have given a buy rating, and 2 have given a strong buy rating for HLN.

Consensus Price Target

$12.33
18.97% Upside

According to the 11 analysts' twelve-month price targets for Haleon, the average price target is $12.33. The highest price target for HLN is $13.40, while the lowest price target for HLN is $11.25. The average price target represents a forecasted upside of 18.97% from the current price of $10.36.

Get the Latest News and Ratings for HLN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Haleon and its competitors.

HLN Analyst Ratings Over Time

Type	Current Forecast 7/1/24 to 7/1/25	1 Month Ago 6/1/24 to 6/1/25	3 Months Ago 4/2/24 to 4/2/25	1 Year Ago 7/2/23 to 7/1/24
Strong Buy	2 Strong Buy rating(s)	2 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	4 Buy rating(s)	4 Buy rating(s)	1 Buy rating(s)	4 Buy rating(s)
Hold	5 Hold rating(s)	5 Hold rating(s)	6 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$12.33	$12.33	$10.95	N/A
Forecasted Upside	18.97% Upside	8.49% Upside	7.78% Upside	N/A
Consensus Rating	Moderate Buy	Moderate Buy	Hold	Moderate Buy

HLN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

HLN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Haleon Stock vs. The Competition

Type	Haleon	Medical Companies	S&P 500
Consensus Rating Score	2.73	2.81	2.53
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	18.97% Upside	8,585.16% Upside	12.11% Upside
News Sentiment Rating	Positive News See Recent HLN News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
5/27/2025	BNP Paribas 4 of 5 stars	M. Omanadze Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/27/2025	BNP Paribas Exane 0 of 5 stars		Upgrade	Neutral ➝ Outperform	$13.40	+20.07%
5/9/2025	Morgan Stanley 3 of 5 stars		Upgrade	Equal Weight ➝ Overweight	$11.25	+6.38%
5/6/2025	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight
3/5/2025	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Fialko Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
3/5/2025	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Hold
3/3/2025	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Hold ➝ Hold
1/8/2025	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Elliott Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
10/1/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	G. Delmas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/6/2024	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	B. Davies Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
8/6/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	O. Nicolai Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
3/26/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy
8/8/2023	Investec Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Sell ➝ Hold

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 04:52 AM ET.

Should I Buy Haleon Stock? HLN Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, June 30, 2025. Please send any questions or comments about these Haleon pros and cons to contact@marketbeat.com.

Haleon
Bull Case

Here are some ways that investors could benefit from investing in Haleon plc:

The stock has recently been rated as a "Moderate Buy" by analysts, indicating positive sentiment and potential for growth.
Haleon plc has a current stock price around $10.39, which is near its 1-year high of $11.42, suggesting it may be positioned for further appreciation.
Recent upgrades from major firms, including a shift to "outperform" by BNP Paribas Exane, reflect growing confidence in the company's performance.
The company has a solid market capitalization of approximately $46.70 billion, indicating a stable financial foundation and investor interest.
Haleon plc operates in the consumer healthcare sector, which tends to be resilient during economic downturns, providing a level of security for investors.

Haleon
Bear Case

Investors should be bearish about investing in Haleon plc for these reasons:

The stock has experienced fluctuations, with a recent trading down of about 0.3%, which may indicate volatility and uncertainty.
Despite positive ratings, five analysts still maintain a "hold" rating, suggesting caution among some market experts.
The company's debt-to-equity ratio of 0.53 indicates a moderate level of debt, which could pose risks if not managed effectively.
Haleon plc's quick ratio of 0.78 and current ratio of 0.98 suggest that the company may face challenges in meeting short-term liabilities, which could affect liquidity.
Market conditions can impact consumer spending on healthcare products, which may affect Haleon's sales and profitability in the future.

HLN Forecast - Frequently Asked Questions

: According to the research reports of 11 Wall Street equities research analysts, the average twelve-month stock price forecast for Haleon is $12.33, with a high forecast of $13.40 and a low forecast of $11.25.
: 11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Haleon in the last twelve months. There are currently 5 hold ratings, 4 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" HLN shares.
: According to analysts, Haleon's stock has a predicted upside of 18.97% based on their 12-month stock forecasts.
: Over the previous 90 days, Haleon's stock had 3 upgrades by analysts.
: Haleon has been rated by research analysts at Barclays, BNP Paribas, BNP Paribas Exane, and Morgan Stanley in the past 90 days.
: Analysts like Haleon less than other "medical" companies. The consensus rating score for Haleon is 2.73 while the average consensus rating score for "medical" companies is 2.81. Learn more on how HLN compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NYSE:HLN) was last updated on 7/1/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Haleon (HLN) Stock Forecast & Price Target